December 31, 2020 Revelation Biosciences, Inc. Re: Global Health Agreement Ladies and Gentlemen:Letter Agreement • November 4th, 2021 • Petra Acquisition Inc. • Pharmaceutical preparations • Delaware
This global health letter agreement (“Global Health Agreement”) is entered into by and between Revelation Biosciences, Inc. a Delaware corporation (the “Company”) and AXA Prime Impact Master Fund I SCA SICAV-RAIF (the “Investor” or “AXA IM Impact Fund”) in connection with its commitment to purchase certain shares of the Company’s Series A Preferred Stock (the “Shares”) in accordance with the terms of that certain Series A Preferred Stock Purchase Agreement dated as of even date herewith (the “Purchase Agreement”), at a price of $6.36 per share (for a total of $3,999,994.80) (the “Investment”).
NOTE CANCELLATION AGREEMENTNote Cancellation Agreement • November 4th, 2021 • Petra Acquisition Inc. • Pharmaceutical preparations • New York
This Note Cancellation Agreement (this “Agreement”), dated as of October 13, 2021, is entered by and between Petra Acquisition, Inc. (the “Borrower”), and Pine Valley Investments LLC (the “Lender”).
